Quality indicators for the care of ischemic heart disease in vulnerable elders

Journal of the American Geriatrics Society

Volumn 55, Issue SUPPL. 2, 2007, Pages

  Watson, Karol ^a,b   Fung, Constance H ^b,c,d   Budoff, Matthew ^b,e  

^a UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^d RAND CORPORATION   (United States)

^e HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

Age; Heart; Ischemia

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT;

AGING; BLEEDING; BLOOD CLOT LYSIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEPRESSION; DISEASE ASSOCIATION; ELDERLY CARE; EVIDENCE BASED PRACTICE; EXERCISE TEST; HEALTH CARE QUALITY; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE REPERFUSION; HEART REHABILITATION; HUMAN; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; META ANALYSIS; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; QUALITY OF LIFE; REVIEW; SMOKING CESSATION; SURVIVAL RATE; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT INDICATION;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DEPRESSION; ECHOCARDIOGRAPHY, STRESS; ESTROGEN REPLACEMENT THERAPY; EVIDENCE-BASED MEDICINE; FRAIL ELDERLY; HUMANS; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION; MYOCARDIAL REVASCULARIZATION; PLATELET AGGREGATION INHIBITORS; PROCESS ASSESSMENT (HEALTH CARE); QUALITY INDICATORS, HEALTH CARE; RISK FACTORS; SMOKING CESSATION; VENTRICULAR DYSFUNCTION, LEFT;

EID: 34848922091     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2007.01344.x     Document Type: Review

References (78)

1. Aguirre FV, McMahon RP, Mueller H et al. Impact of age on clinical outcome and postlytic management strategies in patients treated with intravenous thrombolytic therapy. Results from the TIMI II study. TIMI II investigators. Circulation 1994 90 : 78 86.
2. White HD, Barbash GI, Califf RM et al. Age and outcome with contemporary thrombolytic therapy. Results from the GUSTO-I trial. Global Utilization of Streptokinase and TPA for Occluded coronary arteries trial. Circulation 1996 94 : 1826 1833.
3. Alexander KP, Roe MT, Chen AY et al. Evolution in cardiovascular care for elderly patients with non-ST-segment elevation acute coronary syndromes: Results from the CRUSADE National Quality Improvement Initiative. J Am Coll Cardiol 2005 46 : 1479 1487.
4. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994 308 : 81 106.
5. Lewis HD Jr., Davis JW, Archibald DG et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med 1983 309 : 396 403.
6. The RISC group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990 336 : 827 830.
7. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988 13 : 349 360.
8. Yusuf S, Zhao F, Mehta SR et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001 345 : 494 502.
9. Mehta SR, Yusuf S, Peters RJ et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet 2001 358 : 527 533.
10. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981 304 : 801 807.
11. A randomized trial of propranolol in patients with acute myocardial infarction. II. Morbidity results. JAMA 1983 250 : 2814 2819.
12. First International Study of Infarct Survival Collaborative Group. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. Lancet 1986 2 : 57 66.
13. Hjalmarson A, Elmfeldt D, Herlitz J et al. Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial. Lancet 1981 2 : 823 827.
14. The MIAMI Trial Research Group. Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial. Eur Heart J 1985 6 : 199 226.
15. Krumholz HM, Radford MJ, Wang Y et al. National use and effectiveness of beta-blockers for the treatment of elderly patients after acute myocardial infarction: National Cooperative Cardiovascular Project. JAMA 1998 280 : 623 629.
16. Miettinen TA, Pyorala K, Olsson AG et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: Findings from the Scandinavian Simvastatin Survival Study (4S). Circulation 1997 96 : 4211 4218.
17. Soumerai SB, McLaughlin TJ, Spiegelman D et al. Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction. JAMA 1997 277 : 115 121.
18. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995 345 : 669 685.
19. Hammermeister KE, DeRouen TA, Dodge HT. Variables predictive of survival in patients with coronary disease. Selection by univariate and multivariate analyses from the clinical, electrocardiographic, exercise, arteriographic, and quantitative angiographic evaluations. Circulation 1979 59 : 421 430.
20. Nicolosi GL, Latini R, Marino P et al. The prognostic value of predischarge quantitative two-dimensional echocardiographic measurements and the effects of early lisinopril treatment on left ventricular structure and function after acute myocardial infarction in the GISSI-3 Trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. Eur Heart J 1996 17 : 1646 1656.
21. Ahnve S, Gilpin E, Dittrich H et al. First myocardial infarction: Age and ejection fraction identify a low-risk group. Am Heart J 1988 116 : 925 932.
22. Pierard LA, Albert A, Chapelle JP et al. Relative prognostic value of clinical, biochemical, echocardiographic and haemodynamic variables in predicting in-hospital and one-year cardiac mortality after acute myocardial infarction. Eur Heart J 1989 10 : 24 31.
23. Shaw LJ, Peterson ED, Kesler K et al. A metaanalysis of predischarge risk stratification after acute myocardial infarction with stress electrocardiographic, myocardial perfusion, and ventricular function imaging. Am J Cardiol 1996 78 : 1327 1337.
24. Nyman I, Larsson H, Areskog M et al. The predictive value of silent ischemia at an exercise test before discharge after an episode of unstable coronary artery disease. RISC Study Group. Am Heart J 1992 123 : 324 331.
25. Lindahl B, Andren B, Ohlsson J et al. Risk stratification in unstable coronary artery disease. Additive value of troponin T determinations and pre-discharge exercise tests. FRISK Study Group. Eur Heart J 1997 18 : 762 770.
26. de Belder MA, Pumphrey CW, Skehan JD et al. Relative power of clinical, exercise test, and angiographic variables in predicting clinical outcome after myocardial infarction: The Newham and Tower Hamlets Study. Br Heart J 1988 60 : 377 389.
27. Khattar RS, Basu SK, Raval U et al. Prognostic value of predischarge exercise testing, ejection fraction, and ventricular ectopic activity in acute myocardial infarction treated with streptokinase. Am J Cardiol 1996 78 : 136 141.
28. Wulsin LR, Evans JC, Vasan RS et al. Depressive symptoms, coronary heart disease, and overall mortality in the Framingham Heart Study. Psychosom Med 2005 67 : 697 702.
29. Rugulies R. Depression as a predictor for coronary heart disease. A review and meta-analysis. Am J Prev Med 2002 23 : 51 61.
30. Barth J, Schumacher M, Herrmann-Lingen C. Depression as a risk factor for mortality in patients with coronary heart disease: A meta-analysis. Psychosom Med 2004 66 : 802 813.
31. Rees K, Bennett P, West R et al. Psychological interventions for coronary heart disease. Cochrane Database Syst Rev 2004 (2) : CD002902.
32. Berkman LF, Blumenthal J, Burg M et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: The Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial. JAMA 2003 289 : 3106 3116.
33. Glassman AH, O'Connor CM, Califf RM et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002 288 : 701 709.
34. Carney RM, Blumenthal JA, Freedland KE et al. Depression and late mortality after myocardial infarction in the Enhancing Recovery in Coronary Heart Disease (ENRICHD) study. Psychosom Med 2004 66 : 466 474.
35. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994 343 : 311 322.
36. AIMS Trial Study Group. Effect of intravenous APSAC on mortality after acute myocardial infarction: Preliminary report of a placebo-controlled clinical trial. Lancet 1988 1 : 545 549.
37. The I.S.A.M. Study Group. A prospective trial of intravenous streptokinase in acute myocardial infarction (I.S.A.M.). Mortality, morbidity, and infarct size at 21 days. N Engl J Med 1986 314 : 1465 1471.
38. Wilcox RG, von der Lippe G, Olsson CG et al. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian Study of Early Thrombolysis (ASSET). Lancet 1988 2 : 525 530.
39. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986 1 : 397 402.
40. Fendrick AM, Ridker PM, Bloom BS. Improved health benefits of increased use of thrombolytic therapy. Arch Intern Med 1994 154 : 1605 1609.
41. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI-2): A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990 336 : 65 71.
42. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: A randomised comparison of streptokinase vs. tissue plasminogen activator vs. anistrplase and of aspirin plus heparin vs. aspirin alone among 41,288 cases of suspected acute myocardial infarction. Lancet 1992 339 : 753 770.
43. The International Study Group. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. Lancet 1990 336 : 71 75.
44. The GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993 329 : 673 682.
45. Michels KB, Yusuf S. Does PTCA in acute myocardial infarction affect mortality and reinfarction rates? A quantitative overview (meta-analysis) of the randomized clinical trials. Circulation 1995 91 : 476 485.
46. Stone GW, Brodie BR, Griffin JJ et al. Prospective, multicenter study of the safety and feasibility of primary stenting in acute myocardial infarction: In-hospital and 30-day results of the PAMI stent pilot trial. Primary angioplasty in myocardial infarction stent Pilot trial investigators. J Am Coll Cardiol 1998 31 : 23 30.
47. Berger AK, Schulman KA, Gersh BJ et al. Primary coronary angioplasty vs thrombolysis for the management of acute myocardial infarction in elderly patients. JAMA 1999 282 : 341 348.
48. Ko W, Gold JP, Lazzaro R et al. Survival analysis of octogenarian patients with coronary artery disease managed by elective coronary artery bypass surgery versus conventional medical treatment. Circulation 1992 86 (5 Suppl) : 191 197.
49. Ricou FJ, Suilen C, Rothmeier C et al. Coronary angiography in octogenarians: Results and implications for revascularization. Am J Med 1995 99 : 16 21.
50. Houterman S, Verschuren WM, Hofman A et al. Serum cholesterol is a risk factor for myocardial infarction in elderly men and women: The Rotterdam Study. J Intern Med 1999 246 : 25 33.
51. Shepherd J, Blauw GJ, Murphy MB et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet 2002 360 : 1623 1630.
52. Krumholz HM, Radford MJ, Ellerbeck EF et al. Aspirin for secondary prevention after acute myocardial infarction in the elderly: Prescribed use and outcomes. Ann Intern Med 1996 124 : 292 298.
53. Freemantle N, Cleland J, Young P et al. Beta-blockade after myocardial infarction: Systematic review and meta regression analysis. BMJ 1999 318 : 1730 1737.
54. Hawkins CM, Richardson DW, Vokonas PS. Effect of propranolol in reducing mortality in older myocardial infarction patients. The Beta-Blocker Heart Attack Trial experience. Circulation 1983 67 (6 Part 2) : 94 97.
55. Gundersen T, Abrahamsen AM, Kjekshus J et al. Timolol-related reduction in mortality and reinfarction in patients ages 65-75 years surviving acute myocardial infarction. Prepared for the Norwegian Multicentre Study Group. Circulation 1982 66 : 1179 1184.
56. Andersen MP, Bechsgaard P, Frederiksen J et al. Effect of alprenolol on mortality among patients with definite or suspected acute myocardial infarction. Preliminary results. Lancet 1979 2 : 865 868.
57. Park KC, Forman DE, Wei JY. Utility of beta-blockade treatment for older postinfarction patients. J Am Geriatr Soc 1995 43 : 751 755.
58. Pfeffer MA, Braunwald E, Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. The SAVE Investigators. N Engl J Med 1992 327 : 669 677.
59. Kober L, Torp-Pedersen C, Carlsen JE et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) study group. N Engl J Med 1995 333 : 1670 1676.
60. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993 342 : 821 828.
61. Yusuf S, Sleight P, Pogue J et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N Engl J Med 2000 342 : 145 153.
62. Fox KM. EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003 362 : 782 788.
63. The Peace Trial Investigators. Angio-converting-enzyme inhibition in stable coronary artery disease. N Engl Med 2004 351 : 2058 2068.
64. Hermanson B, Omenn GS, Kronmal RA et al. Beneficial six-year outcome of smoking cessation in older men and women with coronary artery disease. Results from the CASS registry. N Engl J Med 1988 319 : 1365 1369.
65. Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: A systematic review. JAMA 2003 290 : 86 97.
66. Taylor CB, Houston-Miller N, Killen JD et al. Smoking cessation after acute myocardial infarction: Effects of a nurse-managed intervention. Ann Intern Med 1990 113 : 118 123.
67. Fiore M. Treating Tobacco Use and Dependence. Summary. Rockville, MD : U.S. Department of Health and Human Services, Public Health Service, 2000.
68. DeBusk RF, Miller NH, Superko HR et al. A case-management system for coronary risk factor modification after acute myocardial infarction. Ann Intern Med 1994 120 : 721 729.
69. Goldstein MG, Niaura R. Methods to enhance smoking cessation after myocardial infarction. Med Clin North Am 2000 84 : 63 80.
70. Lavie CJ, Milani RV. Effects of cardiac rehabilitation and exercise training programs in patients >or=75 years of age. Am J Cardiol 1996 78 : 675 677.
71. Lavie CJ, Milani RV, Littman AB. Benefits of cardiac rehabilitation and exercise training in secondary coronary prevention in the elderly. J Am Coll Cardiol 1993 22 : 678 683.
72. Lavie CJ, Milani RV. Effects of cardiac rehabilitation programs on exercise capacity, coronary risk factors, behavioral characteristics, and quality of life in a large elderly cohort. Am J Cardiol 1995 76 : 177 179.
73. Lavie CJ, Milani RV. Disparate effects of improving aerobic exercise capacity and quality of life after cardiac rehabilitation in young and elderly coronary patients. J Cardiopulm Rehabil 2000 20 : 235 240.
74. Wenger NK, Froelicher ES, Smith LK et al. Cardiac rehabilitation as secondary prevention. Agency for Health Care Policy and Research and National Heart, Lung, and Blood Institute. Clin Pract Guidel Quick Ref Guide Clin 1995 17 : 1 23.
75. Jolliffe JA, Rees K, Taylor RS et al. Exercise-based rehabilitation for coronary heart disease. Cochrane Database Syst Rev 2001 (1) : CD001800.
76. Hulley S, Grady D, Bush T et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998 280 : 605 613.
77. Rossouw JE, Anderson GL, Prentice RL et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002 288 : 321 333.
78. Anderson GL, Limacher M, Assaf AR et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA 2004 291 : 1701 1712.